89Zr-Df标记双特异性抗PD-L1/TGF-βRII融合蛋白bintrafusp alfa的放射标记及临床前表征
本研究优化了研究性药物bintrafusp alfa及其对照品的89Zr放射标记,并在体外和体内表征89Zr-Df-bintrafusp alfa及对照放射偶联物。在PD-L1/TGF-β阳性EMT-6小鼠乳腺癌模型中,PET/CT生物分布和显像显示89Zr-Df-bintrafusp alfa与89Zr-avelumab的体内分布模式相似,表明bintrafusp alfa的体内分布由其PD-L1结合臂驱动。竞争实验证实了PD-L1靶向的剂量依赖性和特异性,结论是89Zr-Df-bintrafusp alfa的分子显像可行,适用于癌症患者的生物显像临床试验。
要点
- 89Zr-Df-bintrafusp alfa与89Zr-avelumab对PD-L1均达到纳摩尔级亲和力。
- 在EMT-6模型中两者生物分布相似,分布由PD-L1结合臂驱动。
- 竞争实验证实PD-L1靶向的剂量依赖性和特异性。
核心结论
- 89Zr-Df-bintrafusp alfa的分子显像可行,能无创定量肿瘤摄取,适用于癌症患者的生物显像临床试验。
研究设计与样本
- 将bintrafusp alfa、avelumab、同型对照和trap对照用Df螯合后经89Zr放射标记,进行体外放射化学纯度、免疫反应性、抗原结合亲和力和血清稳定性评估。
- 在PD-L1/TGF-β阳性EMT-6小鼠乳腺癌模型中进行PET/CT体内生物分布和显像研究。
- 通过共给予1 mg/kg未标记bintrafusp alfa的竞争性生物分布和显像实验评估特异性。
主要发现
- 89Zr-Df-bintrafusp alfa和89Zr-avelumab对PD-L1达到纳摩尔级亲和力。
- 在PD-L1和TGF-β阳性EMT-6肿瘤荷瘤BALB/c小鼠中,89Zr-Df-bintrafusp alfa与89Zr-avelumab的生物分布和显像显示生物学相似性。
- 与1 mg未标记bintrafusp alfa或avelumab共给予时,竞争实验显示了体内PD-L1靶向的剂量和特异性的影响。
临床怎么用
- 89Zr-Df-bintrafusp alfa PET/CT显像可用于无创定量肿瘤摄取,支持在癌症患者中开展生物显像临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Τhis study aimed to optimize the 89Zr-radiolabelling of bintrafusp alfa investigational drug product and controls, and perform the in vitro and in vivo characterization of 89Zr-Df-bintrafusp alfa and 89Zr-Df-control radioconjugates. METHODS: Bintrafusp alfa (anti-PD-L1 human IgG1 antibody fused to TGF-β receptor II (TGF-βRII), avelumab (anti-PD-L1 human IgG1 control antibody), isotype control (mutated inactive anti-PD-L1 IgG1 control antibody), and trap control (mutated inactive anti-PD-L1 human IgG1 fused to active TGF-βRII) were chelated with p-isothiocyanatobenzyl-desferrioxamine (Df). After radiolabelling with zirconium-89 (89Zr), radioconjugates were assessed for radiochemical purity, immunoreactivity, antigen binding affinity, and serum stability in vitro. In vivo biodistribution and imaging studies were performed with PET/CT to identify and quantitate 89Zr-Df-bintrafusp alfa tumour uptake in a PD-L1/TGF-β-positive murine breast cancer model (EMT-6). Specificity of 89Zr-Df-bintrafusp alfa was assessed via a combined biodistribution and imaging experiment in the presence of competing cold bintrafusp alfa (1 mg/kg). RESULTS: Nanomolar affinities for PD-L1 were achieved with 89Zr-Df-bintrafusp alfa and 89Zr-avelumab. Biodistribution and imaging studies in PD-L1- and TGF-β-positive EMT-6 tumour-bearing BALB/c mice demonstrated the biologic similarity of 89Zr-Df-bintrafusp alfa and 89Zr-avelumab indicating the in vivo distribution pattern of bintrafusp alfa is driven by its PD-L1 binding arm. Competition study with 1 mg of unlabelled bintrafusp alfa or avelumab co-administered with trace dose of 89Zr-labelled bintrafusp alfa demonstrated the impact of dose and specificity of PD-L1 targeting in vivo. CONCLUSION: Molecular imaging of 89Zr-Df-bintrafusp alfa biodistribution was achievable and allows non-invasive quantitation of tumour uptake of 89Zr-Df-bintrafusp alfa, suitable for use in bioimaging clinical trials in cancer patients.
引用
- Burvenich IJG, Goh YW, Guo N, et al. Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. Eur J Nucl Med Mol Imaging. 2021. PMID: 33608805. doi:10.1007/s00259-021-05251-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。